The Scientist - Home

Citing potential worker shortages and the effects of restricted travel and social distancing, the Environmental Protection Agency announced a “sweeping suspension” of environmental regulations that some say gives companies free rein to pollute.

Many researchers have stopped breeding mice, reduced the size of colonies, and established contingency plans in case animal care staff get sick.

Graduate students and postdocs are left wondering about the implications for their academic careers.

Under emergency protocols, doctors can request to use survivors’ plasma to treat some critically ill COVID-19 patients.  

The small number of genetic differences between the original strain of the novel coronavirus from Wuhan and those currently circulating in the US population indicates that a vaccine may likely offer lasting immunity.

Hospitals and commercial companies are testing thousands of patients for COVID-19 daily, but face reagent and supply shortages.

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

The symptoms suggest SARS-CoV-2 might infect neurons, raising questions about whether there could be effects on the brain that play a role in patients’ deaths, but the data are preliminary.

As scores of academic meetings get upended due to COVID-19, researchers are turning to virtual replacements.

We present an economic plan for a collective sharing of scientific knowledge on the pandemic.

President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.

Under lockdown in a hotel, members of a plant ecology course continue to work and study as they seek a way to return home.